Skip to content

Preoperative RESpiratory Training and MOBilization to Prevent Postoperative Pulmonary Complications in Patients Undergoing Thoracic Surgery

Preoperative RESpiratory Training and MOBilization to Prevent Postoperative Pulmonary Complications in Patients Undergoing Thoracic Surgery (RESMOB): A Multi-center Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05416411
Acronym
RESMOB
Enrollment
436
Registered
2022-06-13
Start date
2022-07-20
Completion date
2024-07-10
Last updated
2023-12-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Complications, Procedure, Thoracic Surgical

Keywords

prehabilitation

Brief summary

Postoperative pulmonary complications (PPCs) are the most frequent complications occurring in patients undergoing thoracic surgery and they are associated with prolonged hospital stay, decreased survival and expanding medical costs. Implementation of structured and supervised exercise programs including endurance training (ET), respiratory muscle training (RMT) or a combination of both, within the short waiting period before surgery, has been shown to enhance patients' physical fitness, to provide protective effects against PPCs and therefore to spare health care resources by shortening intensive care unit (ICU) and hospital lengths of stay. More recently, a simple intervention consisting in patient's instruction and education about modifiable risk factors, optimal breathing pattern and the impact of physical exercise has emerged as a simple alternative intervention prevent PPCs, although the evidence is inconclusive. Therefore, the investigators propose a multicentre randomized, open, blinded end point controlled trial testing the hypothesis that preoperative education and instruction focused on breathing exercise and endurance training reduce the occurrence of PPCs in patients undergoing thoracic or abdominal surgery. Patients with Intermediate-to-high risks factors for PPCs will be randomized on a 1:1 basis into an intervention arm and a usual care arm (Control group). In the Education group, patients will be asked to use a flow resistive device (One set of 30 repetitions, two times a day and to increase their daily physical activities (\> 5'000 steps or equivalent) until surgery. Primary study endpoint will be the incidence of PPCs (e.g., atelectasis, pneumonia, respiratory failure) according to the European Perioperative Clinical Outcome definitions. Secondary outcomes will include non-respiratory complications, utilization of hospital resources (e.g., hospital length of stay, ICU admission),and preoperative changes in maximal inspiratory pressure \[MIP\]. Assuming a rate of 39% PPCs in the controls and a possible reduction to 26% in the intervention group, enrollment of 203 patients per group will provide 80% power with an alpha value of 0.05. Taking into account dropouts (5%) and in-hospital mortality rate (2%), a total of 436 surgical patients will be enrolled.

Interventions

BEHAVIORALInspiratory muscle training

Patients will do inspiratory muscle training via a flow resistive device. Priorly, maximum inspiratory pressure will be measured. Afterwards, the training device will be set to 10% increased value of maximum inspiratory pressure (MIP), and the training will be completed two times and 30 repetitions a day during preoperative 7 days. Meanwhile patients will be advised to walk 5000 steps a day during the intervention period.

Sponsors

Istanbul University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients (\> 18 years) * Risk factors for PPCs (ARISCAT score \>27) * Elective intra-abdominal surgery or intrathoracic surgery via an open or minimally-invasive approach, expected to last \> 120 min.

Exclusion criteria

* Patients unable to understand the instructions and/or to perform the proposed training program (i.e., poor comprehension, chest pain) * COPD GOLD Grade III and IV, lung fibrosis, documented bullae, severe emphysema, pneumothorax * Patient with chest pain or at risk of pneumothorax * Previous lung surgery * Bilateral lung procedures * Emergent surgery or organ transplant * Planned mechanical ventilation after surgery * Uncontrolled asthma * Coronary heart disease with angina grade 3 or 4 Canadian Cardiovascular Society * documented pulmonary arterial hypertension \>25mmHg mean pulmonary arterial pressure (PAP) at rest or \> 40 mmHg systolic PAP (estimated by ultrasound) * Documented or suspected neuromuscular disease (thymoma, myasthenia, myopathies, muscular dystrophies, others) * Intracranial injury or tumor * Persistent hemodynamnic instability, intractable shock * Pregnancy (excluded by anamnesis and/or laboratory analysis) * Enrollment in another interventional study or refusal of informed consent * Presence of one of the adverse events, listed as PPCs (aspiration, respiratory failure, pneumonia, atelectasis, cardiopulmonary edema, pleural effusion, pneumothorax) * Pleural surgery only, sympathectomy surgery only, chest wall surgery only, mediastinal surgery only, lung transplantation

Design outcomes

Primary

MeasureTime frameDescription
The incidence of postoperative pulmonary complicationsUp to postoperative 5 daysPostoperative pulmonary complications will be investigated during the postoperative 5 days. These complications are named according to the European Perioperative Clinical Outcome (EPCO) definitions (Respiratory failure, aspiration pneumonitis, pneumonia, ARDS, pneumothorax, atelectasis, bronchospasm)

Secondary

MeasureTime frameDescription
Preoperative MIP change7 daysMaximum inspiratory pressure (MIP) will be measured during the enrollment and the training resistance will be set up according to this value. Once the training completed (after 7 days) another MIP measurement will be made
Length of stay in hospitalUp to 15 daysLength of stay will be recorded as days
Visual Analog Scale thoracic rest painUp to 5 daysPatients will be asked to describe their thoracic rest pain in a scale of 0 to 10
Visual Analog Scale thoracic coughing painUp to 5 daysPatients will be asked to describe their thoracic coughing pain in a scale of 0 to 10
Visual Analog Scale dyspneaUp to 5 daysPatients will be asked to describe their dyspnea in a scale of 0 to 10

Countries

Turkey (Türkiye)

Contacts

Primary ContactEmre S Bingul, MD
emre.bingul@istanbul.edu.tr00902124142000
Backup ContactZerrin Sungur, Prof
zsungur@istanbul.edu.tr00902124142000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026